Cover Image

Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in the intensive care unit

Christy Maggiore,1 Jose A Vazquez,2 David J Guervil,3 Ananthakrishnan Ramani,4 Alena Jandourek,5 Phillip Cole,5 H David Friedland5 1Gulf Coast Medical Center, Panama City, FL, USA; 2Medical College of Georgia, Georgia Regents University, Augusta, GA, USA; 3Memorial Hermann-Texas Medical Center, Hous...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maggiore C (Author), Vazquez JA (Author), Guervil DJ (Author), Ramani A (Author), Jandourek A (Author), Cole P (Author), Friedl (Author), HD (Author)
Format:	Book
Published:	Dove Medical Press, 2015-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Critical appraisal of ceftaroline in the management of community-acquired bacterial pneumonia and skin infections
by: Goodman JJ, et al.
Published: (2012)

Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System
by: Torres A, et al.
Published: (2022)

Ceftaroline Fosamil for the Treatment of Methicillin-Resistant Staphylococcus Aureus Bacteremia: A Real-World Comparative Clinical Outcomes Study
by: Jennifer Hammond, et al.
Published: (2024)

The use of extrapolation based on modeling and simulation to support high‐dose regimens of ceftaroline fosamil in pediatric patients with complicated skin and soft‐tissue infections
by: Phylinda L.S. Chan, et al.
Published: (2021)

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia
by: Mpenge MA, et al.
Published: (2015)

Experience with ceftaroline for treatment of methicillin-resistant Staphylococcus aureus pneumonia in a community hospital
by: Apurwa Karki, et al.
Published: (2017)

Procalcitonin for detecting community-acquired bacterial pneumonia
by: Devi Gusmaiyanto, et al.
Published: (2015)

In Silico Study of Ceftaroline's Molecular Properties
by: Elso Manuel Cruz Cruz, et al.
Published: (2011)

In Silico Study of Ceftaroline's Molecular Properties
by: Elso Manuel Cruz Cruz, et al.
Published: (2011)

Comparative pharmacoeconomic analysis of ceffaroline fosamil in the treatment of complicated skin and soft tissues infections
by: S. K. Zyryanov, et al.
Published: (2018)

Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan
by: Risako Takaya, et al.
Published: (2024)

Present and future etiological treatment of bacterial pneumonia 2. Antibiotic therapy of hospital-acquired pneumonia
by: А.Е. Abaturov, et al.
Published: (2017)

Current and future etiologic therapy of bacterial pneumonia. 1. Antibiotic therapy for community-acquired pneumonia
by: А.Е. Abaturov, et al.
Published: (2017)

Effect of Ceftaroline, Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam on Establishment of Colonization by Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice
by: Bryan Hausman, et al.
Published: (2024)

Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study
by: Ignacio Martin-Loeches, et al.
Published: (2021)

In Vitro Activity of Ceftaroline, Linezolid, and Tigecycline against Staphylococcus aureus and Streptococcus pneumoniae by Infection Site in the Africa/Middle East Region, 2014-17
by: I Morrissey, et al.
Published: (2020)

Nasopharyngeal bacterial carriage and antimicrobial resistance in underfive children with community acquired pneumonia
by: Cissy B. Kartasasmita, et al.
Published: (2001)

Hospital-acquired bacterial infections in COVID-19 intensive care unit: A retrospective cross-sectional study
by: Mirko Mihalj, et al.
Published: (2023)

Severe community-acquired pneumonia: principles of diagnostics and intensive therapy
by: V.I. Chernii
Published: (2023)

Lefamulin - a recently developed antibiotic for treatment of community-acquired bacterial pneumonia (CABP)
by: Leila Abod, et al.
Published: (2023)

Cost-effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
by: Jaesh Naik, et al.
Published: (2023)

Distribution and antibiotic susceptibility of pathogens isolated from adults with hospital-acquired and ventilator-associated pneumonia in intensive care unit
by: Zorana M. Djordjevic, et al.
Published: (2017)

Risk factors for mortality from severe community-acquired pneumonia in hospitalized children transferred to the pediatric intensive care unit
by: Tingting Shi, et al.
Published: (2020)

Bacterial pneumonia score to identify bacterial pneumonia
by: Ied Imilda, et al.
Published: (2015)

In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019-2020
by: Alona Kuraieva, et al.
Published: (2023)

Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials
by: Abdullah A. Alhifany, et al.
Published: (2022)

Spotlight on solithromycin in the treatment of community-acquired bacterial pneumonia: design, development, and potential place in therapy
by: Donald BJ, et al.
Published: (2017)

A "Boil" Being the Clue to Think beyond Typical Bacterial Pathogens in Community-Acquired Pneumonia
by: Jeanna Auriemma
Published: (2022)

Development of a model for the differential diagnosis of community-acquired bacterial pneumonia and viral lung injury in hospitalized adult patients
by: O. A. Kupriushina, et al.
Published: (2024)

Community-Acquired Pneumonia in Children
by: I.L. Vysochina, et al.
Published: (2014)

Mucoactive therapy in community-acquired pneumonia
by: Andrey A. Zaytsev, et al.
Published: (2023)

Pneumonia acquired in the Community
by: María Caridad Fragoso Marchante, et al.
Published: (2007)

Pneumonia acquired in the Community
by: María Caridad Fragoso Marchante, et al.
Published: (2007)

Efficacy and safety of decamethoxin in complex treatment of patients with group III viral-bacterial community-acquired pneumonia
by: O.L. Bororova
Published: (2021)

Characterization and Clonal Diffusion of Ceftaroline Non-Susceptible MRSA in Two Hospitals in Central Italy
by: Gianluca Morroni, et al.
Published: (2021)

In vitro activity of ceftaroline: A novel antibiotic against methicillin-resistant Staphylococcus aureus
by: Vaishali Gaikwad, et al.
Published: (2016)

The Association of Procalcitonin and C-Reactive Protein with Bacterial Infections Acquired during Intensive Care Unit Stay in COVID-19 Critically Ill Patients
by: Simone Campani, et al.
Published: (2023)

Bacterial Community- and Hospital-Acquired Pneumonia in Patients with Critical COVID-19-A Prospective Monocentric Cohort Study
by: Lenka Doubravská, et al.
Published: (2024)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
by: Munjal Patel, et al.
Published: (2022)

Modern approaches to pharmacotherapy of Community-Acquired Pneumonia
by: Anna A. Gavrilova, et al.
Published: (2020)